Journal of Cystic Fibrosis
Volume 9, Issue 4 , Pages 250-256 , July 2010

Year-to-year changes in lung function in individuals with cystic fibrosis

  • Theodore G. Liou

      Affiliations

    • University of Utah; 26 North 1900 East, Salt Lake City, UT 84132-4701, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 801 585 2804; fax: +1 801 585 2661.
    • ,
  • Eric P. Elkin

      Affiliations

    • ICON Clinical Research; 188 Embarcadero, Ste. 200, San Francisco, CA 94105, United States
    • ,
  • David J. Pasta

      Affiliations

    • ICON Clinical Research; 188 Embarcadero, Ste. 200, San Francisco, CA 94105, United States
    • ,
  • Joan R. Jacobs

      Affiliations

    • Genentech, Inc.; 1 DNA Way, South San Francisco, CA 94080, United States
    • ,
  • Michael W. Konstan

      Affiliations

    • Case Western Reserve University; Rainbow Babies and Children's Hospital, 11100 Euclid Avenue, Cleveland, OH 44106, United States
    • ,
  • Wayne J. Morgan

      Affiliations

    • University of Arizona; 1501 N. Campbell Avenue, Tucson, AZ 85724, United States
    • ,
  • Jeffrey S. Wagener

      Affiliations

    • University of Colorado, Children's Hospital, Aurora, CO 80045, United States

Received 10 August 2009 ,Revised 10 March 2010 ,Accepted 16 April 2010.

References 

  1. Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med. Apr 30 1992;326(18):1187–1191
  2. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. Feb 15 2001;153(4):345-52
  3. Schluchter MD, Konstan MW, Davis PB. Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients. Stat Med. May 15 2002;21(9):1271–1287
  4. Shwachman H, Kulczycki LL. Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period. AMA J Dis Child. Jul 1958;96(1):6–15
  5. Taussig LM, Kattwinkel J, Friedewald WT, Di Sant'Agnese PA. A new prognostic score and clinical evaluation system for cystic fibrosis. J Pediatr. Mar 1973;82(3):380–390
  6. Kulich M, Rosenfeld M, Campbell J, Kronmal R, Gibson RL, Goss CH, et al. Disease-specific reference equations for lung function in patients with cystic fibrosis. Am J Respir Crit Care Med. Oct 1 2005;172(7):885–891
  7. Burrows B, Earle RH. Chronic obstructive lung disease. N Engl J Med. May 22 1969;280(21):1183–1184
  8. Mannino DM, Reichert MM, Davis KJ. Lung function decline and outcomes in an adult population. Am J Respir Crit Care Med. May 1 2006;173(9):985–990
  9. Corey M, Edwards L, Levison H, Knowles M. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr. Dec 1997;131(6):809–814
  10. Rosenbluth DB, Wilson K, Ferkol T, Schuster DP. Lung function decline in cystic fibrosis patients and timing for lung transplantation referral. Chest. Aug 2004;126(2):412–419
  11. Javadpour S, Jones A, Brownlee K. Longitudinal analysis of FEV1 changes related to antibiotic therapy in children with cystic fibrosis. Ir Med J. Aug 2007;100(7):529–532
  12. Liou TG, Adler FR, Cahill BC. Testing lung function decline to time lung transplantation. Chest. Jul 2005;128(1):472–473author reply 473-474
  13. Mayer-Hamblett N, Aitken ML, Accurso FJ, Kronmal RA, Konstan MW, Burns JL, et al. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med. Apr 15 2007;175(8):822–828
  14. Sherrill D, Guerra S, Bobadilla A, Barbee R. The role of concomitant respiratory diseases on the rate of decline in FEV1 among adult asthmatics. Eur Respir J. Jan 2003;21(1):95–100
  15. Stanbrook MB. Tiotropium reduced exacerbations but not rate of FEV1 decline in patients with COPD using other respiratory medications. Evid Based Med. Apr 2009;14(2):42–43
  16. Morgan WJ, Butler SM, Johnson CA, Colin AA, FitzSimmons SC, Geller DE, et al. Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatr Pulmonol. Oct 1999;28(4):231–241
  17. Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med. Oct 15 2008;178(8):814–821
  18. Yucesoy B, Kurzius-Spencer M, Johnson VJ, Fluharty K, Kashon ML, Guerra S, et al. Association of cytokine gene polymorphisms with rate of decline in lung function. J Occup Environ Med. Jun 2008;50(6):642–648
  19. Cazzato S, Poletti V, Bernardi F, Loroni L, Bertelli L, Colonna S, et al. Airway inflammation and lung function decline in childhood post-infectious bronchiolitis obliterans. Pediatr Pulmonol. Apr 2008;43(4):381–390
  20. Martínez-García MA, Soler-Cataluña J, Perpiñá-Tordera M, Román-Sánchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. Nov 2007;132(5):1565–1572
  21. Cystic Fibrosis Foundation . Cystic Fibrosis Foundation Patient Registry 2006 Annual Data Report. Bethesda, Maryland: Cystic Fibrosis Foundation; 2007;
  22. Foundation Cystic Fibrosis. Internet. http://www.cff.org/LivingWithCF/CareCenterNetwork/QualityImprovement/Feb 3 2010;Available from
  23. Glindmeyer HW, Diem JE, Jones RN, Weill H. Noncomparability of longitudinally and cross-sectionally determined annual change in spirometry. Am Rev Respir Dis. May 1982;125(5):544–548
  24. Cox DR, Fitzpatrick R, Fletcher AE, Gore SM, Spiegelhalter DJ, Jones DR. Quality-of-life assessment: can we keep it simple?. J R Stat Soc Ser A (Stat Soc). 1992;155(3):353–393
  25. Quanjer PH. A 10year follow up of 180 adults with bronchial asthma: factors important for the decline in lung function. Thorax. Jun 1992;47(6):484
  26. Chaudemanche H, Monnet E, Westeel V, Pernet D, Dubiez A, Perrin C, et al. Respiratory status in dairy farmers in France; cross sectional and longitudinal analyses. Occup Environ Med. Nov 2003;60(11):858–863
  27. Peat JK, Woolcock AJ, Cullen K. Decline of lung function and development of chronic airflow limitation: a longitudinal study of non-smokers and smokers in Busselton, Western Australia. Thorax. Jan 1990;45(1):32–37
  28. Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG. Pulmonary function between 6 and 18years of age. Pediatr Pulmonol. Feb 1993;15(2):75–88
  29. Hankinson JL, Odencrantz John R, Fedan Kathleen B. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. Jan 1 1999;159(1):179–187
  30. Stanojevic S, Wade A, Stocks J, Hankinson J, Coates AL, Pan H, et al. Reference ranges for spirometry across all ages: a new approach. Am J Respir Crit Care Med. Feb 1 2008;177(3):253–260
  31. Johnson C, Butler SM, Konstan MW, Morgan W, Wohl MEB. Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest. Jan 2003;123(1):20–27
  32. Chapman KR, Stockley RA, Dawkins C, Wilkes MM, Navickis RJ. Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. COPD. Jun 2009;6(3):177–184
  33. Konstan MW, Morgan WJ, Butler SM, Pasta DJ, Craib ML, Silva SJ, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr. Aug 2007;151(2):134–139139.e1

PII: S1569-1993(10)00040-8

doi: 10.1016/j.jcf.2010.04.002

Journal of Cystic Fibrosis
Volume 9, Issue 4 , Pages 250-256 , July 2010

Article Tools

* Image Usage & Resolution